Favoino E - Search Results

1

Prete M, Racanelli V, Leone P, Favoino E, Perosa F. Prete M, et al. Among authors: favoino e. Clin Case Rep. 2024 Feb 22;12(2):e8446. doi: 10.1002/ccr3.8446. eCollection 2024 Feb. Clin Case Rep. 2024. PMID: 38389963 Free PMC article.

2

Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide.

Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Perosa F, et al. Among authors: favoino e. J Immunol. 2003 Aug 15;171(4):1918-26. doi: 10.4049/jimmunol.171.4.1918. J Immunol. 2003. PMID: 12902494

3

Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope.

Perosa F, Favoino E, Caragnano MA, Dammacco F. Perosa F, et al. Among authors: favoino e. Immunol Lett. 2004 Sep;95(2):145-53. doi: 10.1016/j.imlet.2004.06.012. Immunol Lett. 2004. PMID: 15388254

4

CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases.

Perosa F, Favoino E, Caragnano MA, Dammacco F. Perosa F, et al. Among authors: favoino e. Ann N Y Acad Sci. 2005 Jun;1051:672-83. doi: 10.1196/annals.1361.112. Ann N Y Acad Sci. 2005. PMID: 16127008

5

CD20: a target antigen for immunotherapy of autoimmune diseases.

Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. Perosa F, et al. Among authors: favoino e. Autoimmun Rev. 2005 Nov;4(8):526-31. doi: 10.1016/j.autrev.2005.04.004. Autoimmun Rev. 2005. PMID: 16214090 Review.

6

Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.

Perosa F, Favoino E, Caragnano MA, Dammacco F. Perosa F, et al. Among authors: favoino e. Blood. 2006 Feb 1;107(3):1070-7. doi: 10.1182/blood-2005-04-1769. Epub 2005 Oct 13. Blood. 2006. PMID: 16223774 Free article.

7

Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease.

Prete M, Perosa F, Favoino E, Dammacco F. Prete M, et al. Among authors: favoino e. Clin Exp Med. 2005 Dec;5(4):141-60. doi: 10.1007/s10238-005-0080-5. Clin Exp Med. 2005. PMID: 16362794 Review.

8

Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy.

Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F. Perosa F, et al. Among authors: favoino e. J Immunol. 2007 Dec 1;179(11):7967-74. doi: 10.4049/jimmunol.179.11.7967. J Immunol. 2007. PMID: 18025245

9

Rheumatic disorders as paraneoplastic syndromes.

Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Racanelli V, et al. Among authors: favoino e. Autoimmun Rev. 2008 May;7(5):352-8. doi: 10.1016/j.autrev.2008.02.001. Epub 2008 Feb 22. Autoimmun Rev. 2008. PMID: 18486921 Review.

10

Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.

Perosa F, Minoia C, Favoino E, Prete M, Dammacco F. Perosa F, et al. Among authors: favoino e. Blood Cells Mol Dis. 2009 Jan-Feb;42(1):71-6. doi: 10.1016/j.bcmd.2008.09.003. Epub 2008 Nov 7. Blood Cells Mol Dis. 2009. PMID: 18996035

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page